Madrid
1 - 2
October
2026
Dr. Alessandro Isidori,
Marche Nord Hospital. Pesaro, Italy
Dr. Carlos Plaza,
UEES Clinic y SOLCA. Guayaquil, Ecuador
Dr. Claudia Núñez-Torrón,
Hospital Universitario Infanta Sofía. Madrid, Spain
Moving toward total oral therapy
Dr. Gabriela Rodríguez Macías,
Hospital General Universitario Gregorio Marañón. Madrid, Spain
Triplets: is this really low-intensity? Venetoclax-based therapies in the U.S.
Dr. Naval Daver,
MD Anderson Cancer Center. Houston, USA
New therapeutic combinations in AML: moving beyond intensive chemotherapy
Dr. Hartmut Döhner,
Universitätsklinikum, Ulm. Ulm, Germany
Discussion
Coffee break
Daily challenges and complex decisions 2. FLT3 AML
Dr. Josefina Serrano,
Hospital Universitario Reina Sofía de Córdoba, Spain
Dr. Mar Tormo,
Hospital Clínico Universitario de Valencia, Spain
Dr. Adolfo de la Fuente,
MD Anderson Cancer Center Madrid-Hospiten, Spain
Discussion
Dr. Gilberto Barranco,
Hospital General de México, Mexico City
Dr. Virginia Abello,
Luis Carlos Sarmiento Angulo Cancer Treatment and Research Center. Bogotá, Colombia
Dr. Mayte Olave,
Hospital Clínico Universitario Lozano Blesa. Zaragoza, Spain
Decisions based on MRD in ALL
Dr. Elias Jabbour,
MD Anderson Cancer Center. Houston, USA
ALL colloquium
First-line treatment for B-ALL in adults: practical tips for day-to-day management
Dr. María Calbacho,
Hospital Universitario 12 de Octubre. Madrid, Spain
Dr. Mónica Cabrero,
Hospital Clínico Universitario de Salamanca, Spain
Discussion
Dr. Carlos Jiménez-Chillón,
Hospital General Universitario Gregorio Marañón, Madrid, Spain
Dr. Joaquín Sánchez,
Hospital Universitario Reina Sofía. Córdoba, Spain
Dr. Adolfo de la Fuente,
MD Anderson Cancer Center Madrid-Hospiten, Spain
Miguel Ángel Sierra,
Account Manager – Healthcare & Life Science, Google
César Tapias,
Data & AI Sales for Health Media Travel & Public, Google
Lunch
Dr. Joana Brioso Infante,
Centro Hospitalar Universitário de Lisboa Norte, Portugal
Dr. Mónica Alejandra Romero,
Hospital Clínico Regional Dr. Guillermo Grant Benavente. Concepción, Chile
Dr. Mika Kontro,
University of Helsinki, Finland
Impact of the redefinition of the MRD (ELN 2025)
Dr. Eva Barragán,
Hospital Universitario y Politécnico La Fe. Valencia, Spain
Colloquium: MRD in AML from prognostic factor to actionable target
Dr. Adolfo de la Fuente,
MD Anderson Cancer Center Madrid-Hospiten, Spain
Dr. Joaquín Sánchez,
Hospital Universitario Reina Sofía. Córdoba, Spain
Dr. Jordi Esteve,
Hospital Clinic de Barcelona, Spain
Dr. Hartmut Döhner,
Universitätsklinikum Ulm, Germany
Discussion
Coffee break
Dr. Mika Kontro,
University of Helsinki, Finland
Dr. Anne Louise Tølbøll Sørensen,
Rigshospitalet Copenhagen University, Denmark
Dr. Jordi Esteve,
Hospital Clinic Barcelona, Spain
AML NPM1 and ALM KMT2A rearrangement: biological basis, oncogenic potential, and mechanisms of resistance
Dr. Joaquín Sánchez,
Hospital Universitario Reina Sofía. Córdoba, Spain
Menin inhibitors in KMT2A-rearranged, NPM1-mutated, and other HOX-expressing leukemias
Dr. Issa Ghayas,
MD Anderson Cancer Center. Houston, USA
Menin inhibitors as monotherapy: from clinical trials to real-world practice
Dr. Cristina Papayannidis,
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy
Discussion
Dr. Isolda Fernández,
Centro de Hematología Pavlovsky. Buenos Aires, Argentina
Dr. Claudia Sossa,
Complejo Médico Fundación Oftalmológica de Santander – Clínica Carlos Ardila Lulle (FOSCAL). Bucaramanga, Colombia
Colloquium
FLT3-mutated AML (low-intensity treatment vs. intensive chemotherapy, transplant for all?)
Dr. Jordi Esteve,
Hospital Clinic Barcelona, Spain
Dr. Alessandro Isidori,
Marche Nord Hospital. Pesaro, Italy
Dr. Naval Daver,
MD Anderson Cancer Center. Houston, USA
Discussion
Closing and farewell
